{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:42:13Z","timestamp":1793893333419,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004196","name":"Odense Universitetshospital","doi-asserted-by":"publisher","award":["123-A5101"],"award-info":[{"award-number":["123-A5101"]}],"id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Human Genetics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ajhg.2026.05.015","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:20:27Z","timestamp":1782228027000},"page":"1570-1577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Homologous recombination deficiency-driven genomic instability in ovarian cancer as an indicator of BRCA1 and BRCA2 variant pathogenicity"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5213-6237","authenticated-orcid":false,"given":"Simon","family":"Schnaiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric R.","family":"Santer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin A.","family":"Csanaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Adel","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain G.","family":"Zeimet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyriaki","family":"Michailidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda B.","family":"Spurdle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajhg.2026.05.015_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100144","article-title":"The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?","volume":"6","author":"Ngoi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ajhg.2026.05.015_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.trsl.2012.01.022","article-title":"Identifying and exploiting defects in the Fanconi anemia\/BRCA pathway in oncology","volume":"160","author":"Stecklein","year":"2012","journal-title":"Transl. Res."},{"key":"10.1016\/j.ajhg.2026.05.015_bib3","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ajhg.2026.05.015_bib4","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ajhg.2026.05.015_bib5","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ajhg.2026.05.015_bib6","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ajhg.2026.05.015_bib7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","article-title":"Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents","volume":"2","author":"Birkbak","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ajhg.2026.05.015_bib8","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.3390\/cancers15113030","article-title":"The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer-A GEICO Study","volume":"15","author":"Fern\u00e1ndez-Serra","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajhg.2026.05.015_bib9","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ajhg.2026.05.015_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ajhg.2026.05.015_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13148-024-01781-0","article-title":"BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer","volume":"16","author":"Fiegl","year":"2024","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.ajhg.2026.05.015_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejca.2023.04.020","article-title":"PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1\/ENGOT-ov25 trial","volume":"188","author":"Loverix","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ajhg.2026.05.015_bib13","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3390\/cancers16112129","article-title":"Stratification of Homologous Recombination Deficiency-Negative High-Grade Ovarian Cancer by the Type of Peritoneal Spread into Two Groups with Distinct Survival Outcomes","volume":"16","author":"Schnaiter","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajhg.2026.05.015_bib14","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ajhg.2026.05.015_bib15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2026.05.015_bib16","series-title":"GeneReviews\u00ae","article-title":"BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer","author":"Petrucelli","year":"1993"},{"key":"10.1016\/j.ajhg.2026.05.015_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.ajhg.2026.05.015_bib18","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/gim.2017.210","article-title":"Modeling the ACMG\/AMP variant classification guidelines as a Bayesian classification framework","volume":"20","author":"Tavtigian","year":"2018","journal-title":"Genet. Med."},{"key":"10.1016\/j.ajhg.2026.05.015_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2024.101228","article-title":"The Clinical Genome Resource (ClinGen): Advancing genomic knowledge through global curation","volume":"27","author":"Andersen","year":"2025","journal-title":"Genet. Med."},{"key":"10.1016\/j.ajhg.2026.05.015_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/humu.21628","article-title":"ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes","volume":"33","author":"Spurdle","year":"2012","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ajhg.2026.05.015_bib21","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ajhg.2026.05.015_bib22","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/humu.20897","article-title":"Genetic evidence and integration of various data sources for classifying uncertain variants into a single model","volume":"29","author":"Goldgar","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ajhg.2026.05.015_bib23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/humu.23818","article-title":"Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification","volume":"40","author":"Parsons","year":"2019","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ajhg.2026.05.015_bib24","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1186\/s13058-014-0474-y","article-title":"Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia","volume":"16","author":"Spurdle","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ajhg.2026.05.015_bib25","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41416-023-02263-5","article-title":"Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2","volume":"128","author":"O\u2019Mahony","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ajhg.2026.05.015_bib26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1086\/521032","article-title":"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes","volume":"81","author":"Easton","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2026.05.015_bib27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41436-019-0729-1","article-title":"Classification of variants of uncertain significance in BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort","volume":"22","author":"Li","year":"2020","journal-title":"Genet. Med."},{"key":"10.1016\/j.ajhg.2026.05.015_bib28","doi-asserted-by":"crossref","first-page":"9961341","DOI":"10.1155\/2023\/9961341","article-title":"A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to BRCA1 and BRCA2","volume":"2023","author":"Zanti","year":"2023","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ajhg.2026.05.015_bib29","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1038\/s41467-025-59979-6","article-title":"Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification","volume":"16","author":"Zanti","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ajhg.2026.05.015_bib30","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41586-024-08349-1","article-title":"Saturation genome editing-based clinical classification of BRCA2 variants","volume":"638","author":"Sahu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ajhg.2026.05.015_bib31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41586-024-08388-8","article-title":"Functional evaluation and clinical classification of BRCA2 variants","volume":"638","author":"Huang","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ajhg.2026.05.015_bib32","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/humu.23641","article-title":"ClinVar at five years: Delivering on the promise","volume":"39","author":"Landrum","year":"2018","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ajhg.2026.05.015_bib33","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3390\/cancers17111819","article-title":"Classification of Gene Variants in a Danish Population with Suspected Predisposition to Hereditary Breast and\/or Ovarian Cancer","volume":"17","author":"Munch","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajhg.2026.05.015_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100445","article-title":"Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance","volume":"37","author":"Romey","year":"2024","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ajhg.2026.05.015_bib35","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/ijgc-2022-004211","article-title":"Homologous recombination deficiency in newly diagnosed FIGO stage III\/IV high-grade epithelial ovarian cancer: a multi-national observational study","volume":"33","author":"Morgan","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ajhg.2026.05.015_bib36","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1158\/1078-0432.CCR-16-2615","article-title":"Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization","volume":"23","author":"Lheureux","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ajhg.2026.05.015_bib37","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ajhg.2026.05.015_bib38","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1158\/2767-9764.CRC-22-0240","article-title":"Ad hoc Analysis of the Phase III ENGOT-OV16\/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects","volume":"2","author":"Mirza","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.ajhg.2026.05.015_bib39","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ajhg.2026.05.015_bib40","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","article-title":"BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","volume":"8","author":"Maxwell","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ajhg.2026.05.015_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2026.106199","article-title":"Integrating breast tumour homologous recombination deficiency status to aid germline BRCA1 and BRCA2 variant classification","volume":"126","author":"Fortuno","year":"2026","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ajhg.2026.05.015_bib42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2307\/2531405","article-title":"Confidence Intervals for the Ratio of Two Binomial Proportions","volume":"40","author":"Koopman","year":"1984","journal-title":"Biometrics"},{"key":"10.1016\/j.ajhg.2026.05.015_bib43","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.3390\/cancers15235633","article-title":"Homologous Recombination Deficiency Detection Algorithms: A Systematic Review","volume":"15","author":"Mark","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["The American Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002929726002259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002929726002259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:24:21Z","timestamp":1789705461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002929726002259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0002929726002259"],"URL":"https:\/\/doi.org\/10.1016\/j.ajhg.2026.05.015","relation":{},"ISSN":["0002-9297"],"issn-type":[{"value":"0002-9297","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Homologous recombination deficiency-driven genomic instability in ovarian cancer as an indicator of BRCA1 and BRCA2 variant pathogenicity","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Human Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajhg.2026.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society of Human Genetics.","name":"copyright","label":"Copyright"}]}}